Strides Pharma Science Limited (STAR)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
301.7
-6.95(-2.25%)

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australasia, North America, Europe, Asia, India, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and oral liquids, as well as semi powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Clavicin, Combiart, Solcer, Melonax, Duotab, and Vitafer brands; and drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

Pricing Updates

TODAY'S HIGH

306.7

TODAY'S LOW

297.8

52 WEEK HIGH

847.8

52 WEEK LOW

263.35

Major Holders

% of Shares Held by
All Insider

31.97%

% of Shares Held by
Institutions

29.14%

% of Float Held by
Institutions

42.83%

Number of Institutions
Holding Shares

40

Company Overview

MARKET CAP

2709.37 Cr.

ETERPRISE VALUE

5316.93 Cr.

NO. OF SHARES

8.98 Cr.

BOOK VALUE

268.144

DIV. YIELD

2.5%

DEBT

2761.50 Cr.

GROSS PROFIT

1894.47 Cr.

CASH

419.76 Cr.

REVENUE

3112.72 Cr.

REVENUE/SHARE

346.928

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Investments-244.87 Cr.156.35 Cr.-149.29 Cr.672.64 Cr.
Change To Liabilities210.77 Cr.-4.59 Cr.154.84 Cr.-49.60 Lakhs
Total cashflows from Investing Activities-520.82 Cr.1306.15 Cr.-148.49 Cr.582.59 Cr.
Net Borrowings137.84 Cr.-1384.33 Cr.407.60 Cr.-711.24 Cr.
Total Cash from Financing Activities-15.79 Cr.-1709.44 Cr.194.26 Cr.-1015.68 Cr.
Other Liabilities0000
Total Assets3.49 Cr.48 Lakhs1.40 Cr.3.63 Cr.
Net Income268.44 Cr.36.39 Cr.324.61 Cr.664.51 Cr.
Change in Cash-56.40 Cr.-183.65 Cr.109.72 Cr.-258.91 Cr.
Effect of Exchange Rate-1.22 Cr.14.84 Cr.3.89 Cr.2.57 Cr.
Total Cash from Operating Activities481.43 Cr.204.78 Cr.60.05 Cr.187.06 Cr.
Depreciation188.82 Cr.173.58 Cr.157.92 Cr.154.03 Cr.
Other Cashflows from Investing Activities25.46 Cr.1319.43 Cr.441.23 Cr.579.16 Cr.
Dividends Paid-17.91 Cr.-30.77 Cr.-17.94 Cr.-44.28 Cr.
Change to Inventory-414.04 Cr.-162.52 Cr.-305.54 Cr.84.08 Cr.
Change to Account Receivables-124.77 Cr.-159.10 Cr.-172.43 Cr.-274.25 Cr.
Other Cashflows from Financing Activities-139.22 Cr.-171.69 Cr.-196.79 Cr.-263.79 Cr.
Change to Net Income334.76 Cr.306.83 Cr.-113.27 Cr.-440.82 Cr.
Capital Expenditures-297.48 Cr.-150 Cr.-329.07 Cr.-402.63 Cr.

Financials

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax275.43 Cr.54.68 Cr.62.39 Cr.79.94 Cr.
Minority Interest37.34 Cr.67.23 Cr.152.95 Cr.154.64 Cr.
Net Income428.22 Cr.373.79 Cr.147.74 Cr.259.15 Cr.
Selling General Administrative570.39 Cr.457.92 Cr.370.71 Cr.533.43 Cr.
Gross Profit1894.47 Cr.1552.79 Cr.1045.65 Cr.1416.55 Cr.
Ebit428.22 Cr.373.79 Cr.147.74 Cr.259.15 Cr.
Operating Income428.22 Cr.373.79 Cr.147.74 Cr.259.15 Cr.
Other Operating Expenses689.57 Cr.547.37 Cr.409.80 Cr.469.92 Cr.
Interest Expense-124.40 Cr.-134.78 Cr.-67.16 Cr.-137.81 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense31.65 Cr.11.32 Cr.-26.85 Cr.5.68 Cr.
Total Revenue3315.87 Cr.2751.97 Cr.2178.37 Cr.2845.11 Cr.
Total Operating Expenses2887.64 Cr.2378.17 Cr.2030.63 Cr.2585.95 Cr.
Cost of Revenue1421.39 Cr.1199.17 Cr.1132.72 Cr.1428.56 Cr.
Total Other Income Expense Net-152.78 Cr.-319.11 Cr.-85.34 Cr.-179.21 Cr.
Discontinued Operations13.94 Cr.-12.76 Cr.240.62 Cr.610.12 Cr.
Net Income from Continuous Ops.243.78 Cr.43.35 Cr.89.25 Cr.74.26 Cr.
Net Income Applicable to Common Shares268.44 Cr.36.39 Cr.324.61 Cr.664.51 Cr.

Balance Sheet

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Intangible Assets618.51 Cr.546.29 Cr.1508.62 Cr.1453.77 Cr.
Capital Surplus1727.26 Cr.1700.83 Cr.1700.08 Cr.1696.94 Cr.
Total Liabilities4201.01 Cr.3557.07 Cr.5177.99 Cr.4090.10 Cr.
Stock Holder Equity2776.66 Cr.2527.41 Cr.2648.70 Cr.2463.65 Cr.
Minority Interest37.34 Cr.67.23 Cr.152.95 Cr.154.64 Cr.
Other Liabilities216.98 Cr.298.81 Cr.228.14 Cr.150.59 Cr.
Total Assets7015.02 Cr.6151.73 Cr.7979.65 Cr.6708.41 Cr.
Common Stock89.68 Cr.89.56 Cr.89.54 Cr.89.50 Cr.
Retained Earnings886.51 Cr.635.45 Cr.778.69 Cr.532.44 Cr.
Other Liabilities369.82 Cr.154.47 Cr.709.19 Cr.639.48 Cr.
Good Will480.54 Cr.428.55 Cr.1377.63 Cr.1082.69 Cr.
Treasury Stock73.19 Cr.101.56 Cr.80.38 Cr.144.77 Cr.
Other Assets987.31 Cr.907.22 Cr.488.45 Cr.423.40 Cr.
Cash125.83 Cr.182.23 Cr.365.88 Cr.256.16 Cr.
Current Liabilities2738.34 Cr.2544.85 Cr.2662.24 Cr.1899.30 Cr.
Long Term Asset Charges198.22 Cr.198.57 Cr.172.88 Cr.123.51 Cr.
Short Long Term Debt196.97 Cr.129.05 Cr.107.88 Cr.22.72 Cr.
Other Stockholder Equity73.19 Cr.101.56 Cr.80.38 Cr.144.77 Cr.
Property Plant Equipment1499.44 Cr.1463.93 Cr.1136.90 Cr.986.81 Cr.
Total Cur. Assets2817.23 Cr.2372.11 Cr.3048.72 Cr.2483.59 Cr.
Long Term Investments611.97 Cr.433.60 Cr.419.31 Cr.278.13 Cr.
Net Tangible Assets1677.61 Cr.1552.56 Cr.-237.55 Cr.-72.81 Cr.
Short Term Investments149.03 Cr.165.18 Cr.271.75 Cr.39.54 Cr.
Net Receivables1147.66 Cr.978.57 Cr.1122.23 Cr.975.60 Cr.
Long Term Debt882.57 Cr.603.90 Cr.1806.51 Cr.1548.59 Cr.
Inventory1200.70 Cr.782.53 Cr.874.15 Cr.552.02 Cr.
Accounts Payable1178.62 Cr.797.74 Cr.888.98 Cr.712.06 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account